EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of novel multispecific antibodies,announced the achiev...
In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significant...
BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced that the Biologics License Application (BLA) for the treatme...
Ascentage Pharma Group International , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commerc...
Initiative will create one of the world's largest multimodal cancer datasets and an integrated suite of AI models and tools to fuel p...
Cloud-based AI application for colorectal cancer prevention: Enhancing detection of clinically significant lesions without compromising safety and workfl...
Agreement Expands Access to Evonik's CARE Brand Medical Grades in the U.S. and Canada Formerra, a leader in performance materials distribution, to...
Preliminary results for 2025: Group sales revenue rises by 7.6 percent to around 3.5 billion euros Positive development in both divi...
Multi-study collaboration leverages SEQSTER's real world data (RWD) platform to support Praxis's portfolio of precision therapies for CNS disorders ...
AI-enabled brown adipose tissue (BAT) phenotype unlocks population-scale human genetic discovery BAT-01 knockdown drives 15% body-weight reduction in ...
Agreement includes eight programmes, including a clinical-ready asset, plus access to advanced AI-driven peptide drug discovery platform and innovati...
Leading GMP cell therapy CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it ha...
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the ...
- Ipsen obtains exclusive option to global license a research program for a selective disease-modifying approach to neurodegenerative diseases ...
© 2026 Biopharma Boardroom. All Rights Reserved.
